Clinical Trials Sponsored by Adagene Inc

Total 35370 results

Adagene (Suzhou) Limited

Completed

Study of ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma

Solid Tumor | Non-Hodgkin Lymphoma

China
Adagene Inc

Terminated

Study of ADG116 in Patients With Advanced/Metastatic Solid Tumors

Solid Tumor

United States
Adagene Inc

Completed

Study of CD137 Agonist ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma

Solid Tumors, Non-Hodgkin Lymphoma

United States
Adagene (Suzhou) Limited

Terminated

Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma

Solid Tumor | Non Hodgkin Lymphoma

China
Adagene Inc

Recruiting

Study of ADG206 in Subjects With Advanced/Metastatic Solid Tumors

Advanced/Metastatic Solid Tumors

Australia
Adagene Inc

Recruiting

ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors

Advanced/Metastatic Solid Tumors

Singapore, Australia, United States
Adagene Inc

Active, not recruiting

A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients

Advanced/Metastatic Solid Tumors

United States, Australia
Adagene Inc
Merck Sharp & Dohme LLC

Recruiting

ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

Advanced/Metastatic Solid Tumors

Korea, Republic of, United States
National University Hospital, Singapore
Adagene Inc

Recruiting

A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer

Advanced Solid Tumor | HER2-negative Breast Cancer

Singapore
Adagene Inc
Merck Sharp & Dohme LLC

Completed

ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

Advanced/Metastatic Solid Tumors

United States
EdiGene (GuangZhou) Inc.

Active, not recruiting

A Safety and Efficacy Study Evaluating ET-01 in Subjects With Transfusion Dependent β-Thalassaemia (ET-01)

Transfusion Dependent Beta-Thalassaemia

China
OvaGene Oncology, Inc.

Unknown

DNA Single Nucleotide Polymorphisms as Predictors of Toxicity

Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms

United States
Hoffmann-La Roche
Tempest Therapeutics; Adagene Inc

Recruiting

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

Advanced Liver Cancers

Korea, Republic of, Taiwan, United States, Israel, China, France, New Zealand
Aldagen

Terminated

ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases (UCBT-002)

Mucopolysaccharidosis | Inborn Errors of Metabolism | Lysosomal Storage Disorders | Inherited Metabolic Diseases | Peroxisomal Storage Diseases

United States
Aldagen

Unknown

Study of ALD-401 Via Intracarotid Infusion in Ischemic Stroke Subjects

Stroke | Ischemic Stroke | Stroke in Middle Cerebral Artery (MCA)

United States
Aldagen

Completed

ALD-301 for Critical Limb Ischemia, Randomized Trial (CLI-001)

Peripheral Arterial Disease | Peripheral Vascular Disease | Critical Limb Ischemia

United States
Advagene Biopharma Co. Ltd.

Completed

A Phase 2, Double-blind Study to Evaluate Intranasal Trivalent Influenza Virus Vaccine in Healthy Adult

Influenza Infection

Taiwan
EdiGene (GuangZhou) Inc.
PLA 923 Hospital

Active, not recruiting

A Study to Evaluate the Safety and Efficacy of ET-01 Transplantation in Subjects With Transfusion Dependent β-Thalassaemia.

Transfusion Dependent Beta-Thalassaemia

China
National University Hospital, Singapore
Merck Sharp & Dohme LLC; Adagene Inc

Recruiting

Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer (ComPACT)

Triple Negative Breast Cancer | Advanced Solid Tumor

Singapore
Advagene Biopharma Co. Ltd.

Completed

Evaluating Safety, Tolerability, and Potential Efficacy of Intranasal AD17002 in Adults With Mild to Moderate COVID-19

COVID-19

Taiwan
AskGene Pharma, Inc.
Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Recruiting

ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

China
AskGene Pharma, Inc.
Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Not yet recruiting

A Phase 1 Study of ASKG315 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

Australia
Chinese PLA General Hospital
Peking University; EdiGene Inc.

Recruiting

TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL

Non Hodgkin's Lymphoma

China
AskGene Pharma, Inc.
Suzhou Aosaikang Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study of ASKG712 in Patients With Diabetic Macular Edema

Diabetic Macular Edema

China
AskGene Pharma, Inc.
Suzhou Aosaikang Biopharmaceutical Co., Ltd.

Recruiting

A Study of ASKG712 in Patients With Neovascular Age-Related Macular Degeneration

Neovascular Age-related Macular Degeneration

China
National University Hospital, Singapore
Bristol-Myers Squibb; Adagene Inc; Singapore Translational Cancer Consortium

Recruiting

A Study to Evaluate the Combination of Nivolumab With ADG106 in Metastatic NSCLC (ADIVO Lung)

Metastatic Non Small Cell Lung Cancer

Singapore
AskGene Pharma, Inc.
Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Recruiting

A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.

Advanced Solid Tumors

United States
AskGene Pharma, Inc.
Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Recruiting

ASKB589 in Combination With CAPOX and Sintilimab in Patients With Advanced, and Unresectable G/GEJ Cancer.

Gastric Cancer

China
AskGene Pharma, Inc.
Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Recruiting

A Study of ASKG315 in Patients With Advanced Solid Tumors.

Advanced Solid Tumors

China
Advagene Biopharma Co. Ltd.
Gadjah Mada University

Recruiting

Evaluating the Safety and Efficacy of AD17002 Intranasal Spray in Treating Participants With Mild to Moderate COVID-19

COVID-19

Indonesia
Joanne Kurtzberg, MD
Aldagen

Withdrawn

Fetal Umbilical Cord Blood (UCB) Transplant for Lysosomal Storage Diseases (IUHST-001)

Lysosomal Storage Diseases | Inborn Errors of Metabolism

United States
Advagene Biopharma Co. Ltd.
Taipei Medical University Hospital

Recruiting

AD17002 Treating Poorly Controlled, Moderate to Severe Eosinophilic Asthma

Eosinophilic Asthma

Taiwan
Advagene Biopharma Co. Ltd.
National Taiwan University Hospital

Completed

Study of the Safety, Tolerability and Immunogenicity of an Intranasal Influenza Vaccine Administered to Healthy Adults

Flu, Human

Taiwan
Advagene Biopharma Co. Ltd.
Taipei Medical University; Clinipace Worldwide

Completed

Tolerability and Potential Efficacy of LTh(αΚ) in Subjects With Allergic Rhinitis

Allergic Rhinitis

Taiwan
Joanne Kurtzberg, MD
Aldagen

Completed

Unrelated Umbilical Cord Blood Transplantation Augmented With ALDHbr Umbilical Cord Blood Cells

Anemia, Aplastic | MDS | Inborn Errors of Metabolism | Congenital Marrow Failure | Congenital Immunodeficiency Syndrome

United States
University Hospital, Montpellier
ADENE

Recruiting

Sleep Respiratory Disorders in Patients With Moderate to Severe Persistent Rhinitis (JawRhin1)

Rhinitis

France
Shanghai BDgene Co., Ltd.
Ruijin Hospital

Not yet recruiting

Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent β-thalassemia

β-thalassemia

China
EdiGene Inc.
The First Affiliated Hospital of Henan University of Science and Technology; Changping Laboratory

Recruiting

A Study to Evaluate the Safety and Efficacy of ATHENA CAR-T in Subjects With Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic

China
EdiGene (GuangZhou) Inc.
The First Affiliated Hospital of Henan University of Science and Technology

Active, not recruiting

A Study of ET-02 in Patients With Relapsed or Refractory B-cell Malignancy(NHL/ALL)

Relapsed or Refractory B-cell Malignancy(NHL/ALL)

China
Texas Heart Institute
Aldagen; CHI St. Luke's Health, Texas

Active, not recruiting

Intramyocardial Injection of Autologous Aldehyde Dehydrogenase-Bright Stem Cells for Therapeutic Angiogenesis (FOCUS Br)

Coronary Artery Disease

United States
Shanghai BDgene Co., Ltd.
Shanghai Children's Medical Center

Not yet recruiting

Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent Beta-thalassemia

β-thalassemia
Shanghai BDgene Co., Ltd.
Eye & ENT Hospital of Fudan University

Recruiting

VEGFA-targeting Gene Therapy to Treat Retinal and Choroidal Neovascularization Diseases

Diabetic Macular Edema | Retinal Vein Occlusion | Neovascular Age-related Macular Degeneration

China
Shanghai BDgene Co., Ltd.
Eye & ENT Hospital of Fudan University

Completed

Safety and Efficacy of CRISPR/Cas9 mRNA Instantaneous Gene Editing Therapy to Treat Refractory Viral Keratitis

Cornea | Herpes Simplex Virus Infection | Viral Keratitis | Blindness Eye

China
IND Diagnostic Inc.

Unknown

Evaluation of the IND One Step Strep A Rapid Test vs. Culture

Strep Throat

United States
Institute of Hematology & Blood Diseases Hospital...
EdiGene Inc.; The Affiliated Hospital Of Guizhou Medical University; Zunyi Medical...

Active, not recruiting

Safety and Efficacy Evaluation of ET-01 Transplantation in Subjects With Transfusion Dependent β-Thalassaemia

Transfusion Dependent Beta-Thalassaemia

China
UNC Lineberger Comprehensive Cancer Center
Genentech, Inc.; Oncoceutics, Inc.

Recruiting

ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer

Metastasis | Endometrial Cancer

United States
NC Medial Research Inc

Recruiting

A Study of NCS-01 in Patients With Acute Ischemic Stroke

Ischemic Stroke

United States
IC-IT Sciences Inc.

Unknown

Comparison of the Natural Frequencies Technology Sleep Patches to Sham Patches During Sleep in the Home Environment

Sleep Disturbance

United States
Zhengzhou Gensciences Inc
Haimen Gensciences lnc

Completed

An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.

Hemophilia A

China
Zhengzhou Gensciences Inc
Jiangsu Gensciences lnc.

Completed

Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A (RH-107-III02)

Hemophilia A

China

Clinical Trials Sponsored by Adagene Inc

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Italy

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations